Overdose Clause Samples

Overdose. You can die from an overdose of opioid medications. The risk of dangerous overdose is higher if you take opioids combined with alcohol or other medications that can make you sleepy (See Appendix I). Most overdoses are unintentional and can happen to anyone taking opioid medication. a. There is a medicine called Naloxone (Narcan®) that can save your life. It is available at some pharmacies and does not require a prescription. We recommend you get it, but it is not a requirement of this agreement.

Overdose. Overdose by the patient, or other people who have access to these medications, may impair breathing, and lead to coma or death.

Overdose. Unintentional overdose of prescription opioids as well as non-prescribed opioids such as heroin can lead to death. Having multiple opioid prescriptions from different prescribers (doctor shopping) also increases the likelihood of overdose. provider and in Massachusetts it is also available without a prescription at retail pharmacies. While there is information to educate you, your family, and close friends on how to use it, we encourage you to talk to your treating provider to learn more and be educated on how to use it. Patient-Centered Zero Tolerance Policy for Inpatient Opioid Misuse In order to provide safe and high-quality care, we screen patients for opioid dependence, misuse, and/or addiction. Our focus is to treat you with respect in a non- judgmental manner. It is important that you work with your treating provider to share information regarding your use of opioids and/or other drugs, including alcohol and street drugs. Your previous history of drug use and family history are very important to developing your treatment plan. A witnessed urine or blood drug screening may also be requested at any time to further help us in our treatment plan for you. We may also ask that you permit us to search you and your belongings. We may also ask your visitors to be searched as well as their belongings, when the need for this arises. We ask that you comply with us throughout this process. Our goal is to work with you to treat your addiction to opioids or other substances, and to assist you on the journey to recovery. Prohibited items pose a safety risk to you and/or others and include, but are not limited to: drug paraphernalia; prescribed drugs, including opioids; use of alcohol; and controlled substances, including heroin. For your safety and that of other patients and our staff, we will remove all prohibited substances if discovered. Family and Visitors A patient’s family and visitors can play a major role in the treatment and recovery of their loved ones. We invite family members, designated patient representatives, caregivers, and visitors to read this policy and to learn about addiction and why it matters to have the cooperation of loved ones. Although we are welcoming to families and loved ones, there are times when we cannot accommodate visitation or interaction with patients. As written in this document and the Inpatient Opioid Misuse Prevention Policy, we ask all visitors to comply with us as we work hard to ensure the safety of all patients and staff...

Overdose. This refers to the administration of a quantity of a medicinal product given per administration or cumulatively, which is above the maximum recommended dose according to the authorized product information. A patient support programme is an organized system where a marketing authorization holder receives and collects information relating to the use of its medicinal products. Examples are post-authorization patient support and disease management programmes, surveys of patients and healthcare providers, information gathering on patient compliance, or compensation/re-imbursement schemes.

Overdose. To date, no cases of overdosage with budesonide are known. In view of the properties of budesonide contained in Budenofalk 3 mg, an overdose resulting in toxic damage is extremely unlikely.

Overdose. There is no known treatment/antidote available for MIRV. For IC Chemo agents, please follow management guidelines for overdose as described in the prescribing information and/or institutional guidelines. Supportive measures should be instituted if an instance arises in which a patient suffers an overdose of any study drug.

Overdose. The highest dose of binimetinib evaluated as single agent in clinical studies was 80 mg administered orally twice daily and was associated with ocular (chorioretinopathy) and skin toxicities (dermatitis acneiform). There is no specific treatment of overdose. If overdose occurs, the patient should be treated supportively with appropriate monitoring as necessary. Since binimetinib is highly bound to plasma proteins, haemodialysis is likely to be ineffective in the treatment of overdose with binimetinib.

Overdose. Overdoses, regardless of presence of associated clinical manifestation(s) (eg, headache, abnormal laboratory value) will be considered an AE and recorded as such on the eCRF. Any clinical manifestation(s) of overdose must also be recorded as an AE on the eCRF. In addition, all overdoses must be recorded on an Overdose form and sent to Sage or designee within 24 hours of the site becoming aware of the overdose.

Overdose. An overdose is defined as administration of a dose that is over 50 mg/kg. An overdose is not an AE. An overdose will be reported even if it does not result in an AE. An overdose will be recorded in the source documents and reported to the Sponsor or designee within 24 hours.